Global Biosimilars Treatment Market

Biosimilars Treatment Comprehensive Study by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interferons}, Recombinant Glycosylated Proteins {Erythropoietin (EPO),Monoclonal Antibodies (MABS), Follitropin}, Recombinant Peptides {Glucagon, Calcitonin}), Application (Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other), Manufacturing (In-House Manufacturing, Contract Manufacturing) Players and Region - Global Market Outlook to 2030

Biosimilars Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Biosimilars Treatment
The Biosimilars are the chemicals based drugs which are approved by U.S. Food and Drugs Administration (FDA) for the treatment of cancer. Biosimilars treatment market is expected to mark significant growth over forecasted period owing to increasing due to product introduction competition into the drug development process, that leads to cost savings for patients and spurs for development of new treatments and technological advancement. Furthermore, factors such as high demand for the low-cost therapeutics and treatments, high prevalence and incidence of various chronic diseases, rise in research and development expenditures by the market players in the emerging economies such as India, South Korea and China are also propelling the growth of biosimilars market in Asia Pacific region.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Biosimilars Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), Eli Lilly and Company (United States), Celltrion Healthcare (South Korea), Mylan NV (United States), Novartis AG (Switzerland), Samsung Bioepis Co. Ltd (South Korea), Stada Arzneimittel AG (Germany), Teva Pharmaceutical Industries Ltd (Israel) and Intas Pharmaceuticals Ltd (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are LG Life Sciences (South Korea), Biocon (India) and Dr. Reddy’s Laboratories (India).

Segmentation Overview
AMA Research has segmented the market of Global Biosimilars Treatment market by Type (Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interferons}, Recombinant Glycosylated Proteins {Erythropoietin (EPO),Monoclonal Antibodies (MABS), Follitropin} and Recombinant Peptides {Glucagon, Calcitonin}), Application (Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases and Other) and Region.



On the basis of geography, the market of Biosimilars Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Manufacturing, the sub-segment i.e. In-House Manufacturing will boost the Biosimilars Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Collaboration and Tie Up Of Leading Players and Substitutes Available For Biosimilars Treatment

Market Growth Drivers:
Increase Number of Chronic Diseases Boost the Biosimilars Treatment Market. and Rapid Demand of Biosimiliars due to its Cost Effectiveness.

Challenges:
Limitation due to Government Regulations Anticipated to Challenge the Market. and Limited Obtainability of Biosimilar Products Hampers the Global Market.

Restraints:
Complexities in Manufacturing Hampers the Biosimilars Treatment Market. and Lack of Innovative Techniques by the Biosimilars Manufacturers.

Opportunities:
Proliferation of Biosimilars Treatment at Emerging Countries. and Patents Expiry and New Indications of Biologic Products.

Market Leaders and their expansionary development strategies
In November 2022, Biocon Biologics Completed Acquisition of Viatris’ Global Biosimilars Business. The acquisition will accelerates direct commercialization of its biosimilars portfolio in advanced markets and several emerging markets
In October 2023, Boehringer Ingelheim (BI) launched an unbranded version of its adalimumab biosimilar; Alvotech and Kashiv Biosciences partner for an omalizumab biosimilar candidate; the FDA issues a complete response letter (CRL) for Biocon’s insulin aspart biosimilar.
“According to Food and Drug Administration, it’s approved biosimilar products and provides the scientific and regulatory advice needed to bring safe and effective biosimilars to market. The approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs.”

Key Target Audience
Biosimilars Treatment Manufacturers, Biosimilars Treatment Traders, End-Use Market Participants of Different Segments of Biosimilars Treatment, Government and Research Organizations, R&D Institutions and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interferons}
  • Recombinant Glycosylated Proteins {Erythropoietin (EPO),Monoclonal Antibodies (MABS), Follitropin}
  • Recombinant Peptides {Glucagon, Calcitonin}
By Application
  • Oncology
  • Chronic Diseases
  • Autoimmune Diseases
  • Blood Disorders
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other
By Manufacturing
  • In-House Manufacturing
  • Contract Manufacturing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase Number of Chronic Diseases Boost the Biosimilars Treatment Market.
      • 3.2.2. Rapid Demand of Biosimiliars due to its Cost Effectiveness.
    • 3.3. Market Challenges
      • 3.3.1. Limitation due to Government Regulations Anticipated to Challenge the Market.
      • 3.3.2. Limited Obtainability of Biosimilar Products Hampers the Global Market.
    • 3.4. Market Trends
      • 3.4.1. Collaboration and Tie Up Of Leading Players
      • 3.4.2. Substitutes Available For Biosimilars Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biosimilars Treatment, by Type, Application, Manufacturing and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Biosimilars Treatment (Value)
      • 5.2.1. Global Biosimilars Treatment by: Type (Value)
        • 5.2.1.1. Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interferons}
        • 5.2.1.2. Recombinant Glycosylated Proteins {Erythropoietin (EPO),Monoclonal Antibodies (MABS), Follitropin}
        • 5.2.1.3. Recombinant Peptides {Glucagon, Calcitonin}
      • 5.2.2. Global Biosimilars Treatment by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Chronic Diseases
        • 5.2.2.3. Autoimmune Diseases
        • 5.2.2.4. Blood Disorders
        • 5.2.2.5. Growth Hormone Deficiency
        • 5.2.2.6. Infectious Diseases
        • 5.2.2.7. Other
      • 5.2.3. Global Biosimilars Treatment by: Manufacturing (Value)
        • 5.2.3.1. In-House Manufacturing
        • 5.2.3.2. Contract Manufacturing
      • 5.2.4. Global Biosimilars Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Biosimilars Treatment (Price)
      • 5.3.1. Global Biosimilars Treatment by: Type (Price)
  • 6. Biosimilars Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celltrion Healthcare (South Korea)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan NV (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Samsung Bioepis Co. Ltd (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Stada Arzneimittel AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Intas Pharmaceuticals Ltd (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Biosimilars Treatment Sale, by Type, Application, Manufacturing and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Biosimilars Treatment (Value)
      • 7.2.1. Global Biosimilars Treatment by: Type (Value)
        • 7.2.1.1. Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interferons}
        • 7.2.1.2. Recombinant Glycosylated Proteins {Erythropoietin (EPO),Monoclonal Antibodies (MABS), Follitropin}
        • 7.2.1.3. Recombinant Peptides {Glucagon, Calcitonin}
      • 7.2.2. Global Biosimilars Treatment by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Chronic Diseases
        • 7.2.2.3. Autoimmune Diseases
        • 7.2.2.4. Blood Disorders
        • 7.2.2.5. Growth Hormone Deficiency
        • 7.2.2.6. Infectious Diseases
        • 7.2.2.7. Other
      • 7.2.3. Global Biosimilars Treatment by: Manufacturing (Value)
        • 7.2.3.1. In-House Manufacturing
        • 7.2.3.2. Contract Manufacturing
      • 7.2.4. Global Biosimilars Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Biosimilars Treatment (Price)
      • 7.3.1. Global Biosimilars Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biosimilars Treatment: by Type(USD Million)
  • Table 2. Biosimilars Treatment Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interferons} , by Region USD Million (2018-2023)
  • Table 3. Biosimilars Treatment Recombinant Glycosylated Proteins {Erythropoietin (EPO),Monoclonal Antibodies (MABS), Follitropin} , by Region USD Million (2018-2023)
  • Table 4. Biosimilars Treatment Recombinant Peptides {Glucagon, Calcitonin} , by Region USD Million (2018-2023)
  • Table 5. Biosimilars Treatment: by Application(USD Million)
  • Table 6. Biosimilars Treatment Oncology , by Region USD Million (2018-2023)
  • Table 7. Biosimilars Treatment Chronic Diseases , by Region USD Million (2018-2023)
  • Table 8. Biosimilars Treatment Autoimmune Diseases , by Region USD Million (2018-2023)
  • Table 9. Biosimilars Treatment Blood Disorders , by Region USD Million (2018-2023)
  • Table 10. Biosimilars Treatment Growth Hormone Deficiency , by Region USD Million (2018-2023)
  • Table 11. Biosimilars Treatment Infectious Diseases , by Region USD Million (2018-2023)
  • Table 12. Biosimilars Treatment Other , by Region USD Million (2018-2023)
  • Table 13. Biosimilars Treatment: by Manufacturing(USD Million)
  • Table 14. Biosimilars Treatment In-House Manufacturing , by Region USD Million (2018-2023)
  • Table 15. Biosimilars Treatment Contract Manufacturing , by Region USD Million (2018-2023)
  • Table 16. South America Biosimilars Treatment, by Country USD Million (2018-2023)
  • Table 17. South America Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 18. South America Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 19. South America Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 20. Brazil Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 21. Brazil Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 22. Brazil Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 23. Argentina Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 24. Argentina Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 25. Argentina Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 26. Rest of South America Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 29. Asia Pacific Biosimilars Treatment, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 33. China Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 34. China Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 35. China Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 36. Japan Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 37. Japan Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 38. Japan Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 39. India Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 40. India Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 41. India Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 42. South Korea Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 43. South Korea Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 44. South Korea Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 45. Taiwan Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 46. Taiwan Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 47. Taiwan Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 48. Australia Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 49. Australia Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 50. Australia Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 54. Europe Biosimilars Treatment, by Country USD Million (2018-2023)
  • Table 55. Europe Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 56. Europe Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 57. Europe Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 58. Germany Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 59. Germany Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 60. Germany Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 61. France Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 62. France Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 63. France Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 64. Italy Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 65. Italy Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 66. Italy Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 67. United Kingdom Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 69. United Kingdom Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 70. Netherlands Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 71. Netherlands Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 72. Netherlands Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 73. Rest of Europe Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 75. Rest of Europe Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 76. MEA Biosimilars Treatment, by Country USD Million (2018-2023)
  • Table 77. MEA Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 78. MEA Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 79. MEA Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 80. Middle East Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 81. Middle East Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 82. Middle East Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 83. Africa Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 84. Africa Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 85. Africa Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 86. North America Biosimilars Treatment, by Country USD Million (2018-2023)
  • Table 87. North America Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 88. North America Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 89. North America Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 90. United States Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 91. United States Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 92. United States Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 93. Canada Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 94. Canada Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 95. Canada Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 96. Mexico Biosimilars Treatment, by Type USD Million (2018-2023)
  • Table 97. Mexico Biosimilars Treatment, by Application USD Million (2018-2023)
  • Table 98. Mexico Biosimilars Treatment, by Manufacturing USD Million (2018-2023)
  • Table 99. Biosimilars Treatment: by Type(USD/Units)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Biosimilars Treatment: by Type(USD Million)
  • Table 110. Biosimilars Treatment Recombinant Non-Glycosylated Proteins {Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor (Filgrastim), Insulin, Interferons} , by Region USD Million (2025-2030)
  • Table 111. Biosimilars Treatment Recombinant Glycosylated Proteins {Erythropoietin (EPO),Monoclonal Antibodies (MABS), Follitropin} , by Region USD Million (2025-2030)
  • Table 112. Biosimilars Treatment Recombinant Peptides {Glucagon, Calcitonin} , by Region USD Million (2025-2030)
  • Table 113. Biosimilars Treatment: by Application(USD Million)
  • Table 114. Biosimilars Treatment Oncology , by Region USD Million (2025-2030)
  • Table 115. Biosimilars Treatment Chronic Diseases , by Region USD Million (2025-2030)
  • Table 116. Biosimilars Treatment Autoimmune Diseases , by Region USD Million (2025-2030)
  • Table 117. Biosimilars Treatment Blood Disorders , by Region USD Million (2025-2030)
  • Table 118. Biosimilars Treatment Growth Hormone Deficiency , by Region USD Million (2025-2030)
  • Table 119. Biosimilars Treatment Infectious Diseases , by Region USD Million (2025-2030)
  • Table 120. Biosimilars Treatment Other , by Region USD Million (2025-2030)
  • Table 121. Biosimilars Treatment: by Manufacturing(USD Million)
  • Table 122. Biosimilars Treatment In-House Manufacturing , by Region USD Million (2025-2030)
  • Table 123. Biosimilars Treatment Contract Manufacturing , by Region USD Million (2025-2030)
  • Table 124. South America Biosimilars Treatment, by Country USD Million (2025-2030)
  • Table 125. South America Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 126. South America Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 127. South America Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 128. Brazil Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 129. Brazil Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 130. Brazil Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 131. Argentina Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 132. Argentina Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 133. Argentina Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 134. Rest of South America Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 135. Rest of South America Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 136. Rest of South America Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 137. Asia Pacific Biosimilars Treatment, by Country USD Million (2025-2030)
  • Table 138. Asia Pacific Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 139. Asia Pacific Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 140. Asia Pacific Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 141. China Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 142. China Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 143. China Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 144. Japan Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 145. Japan Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 146. Japan Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 147. India Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 148. India Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 149. India Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 150. South Korea Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 151. South Korea Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 152. South Korea Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 153. Taiwan Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 154. Taiwan Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 155. Taiwan Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 156. Australia Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 157. Australia Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 158. Australia Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 162. Europe Biosimilars Treatment, by Country USD Million (2025-2030)
  • Table 163. Europe Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 164. Europe Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 165. Europe Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 166. Germany Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 167. Germany Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 168. Germany Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 169. France Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 170. France Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 171. France Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 172. Italy Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 173. Italy Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 174. Italy Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 175. United Kingdom Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 176. United Kingdom Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 177. United Kingdom Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 178. Netherlands Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 179. Netherlands Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 180. Netherlands Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 181. Rest of Europe Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 182. Rest of Europe Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 183. Rest of Europe Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 184. MEA Biosimilars Treatment, by Country USD Million (2025-2030)
  • Table 185. MEA Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 186. MEA Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 187. MEA Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 188. Middle East Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 189. Middle East Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 190. Middle East Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 191. Africa Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 192. Africa Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 193. Africa Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 194. North America Biosimilars Treatment, by Country USD Million (2025-2030)
  • Table 195. North America Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 196. North America Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 197. North America Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 198. United States Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 199. United States Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 200. United States Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 201. Canada Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 202. Canada Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 203. Canada Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 204. Mexico Biosimilars Treatment, by Type USD Million (2025-2030)
  • Table 205. Mexico Biosimilars Treatment, by Application USD Million (2025-2030)
  • Table 206. Mexico Biosimilars Treatment, by Manufacturing USD Million (2025-2030)
  • Table 207. Biosimilars Treatment: by Type(USD/Units)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biosimilars Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Biosimilars Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Biosimilars Treatment: by Manufacturing USD Million (2018-2023)
  • Figure 7. South America Biosimilars Treatment Share (%), by Country
  • Figure 8. Asia Pacific Biosimilars Treatment Share (%), by Country
  • Figure 9. Europe Biosimilars Treatment Share (%), by Country
  • Figure 10. MEA Biosimilars Treatment Share (%), by Country
  • Figure 11. North America Biosimilars Treatment Share (%), by Country
  • Figure 12. Global Biosimilars Treatment: by Type USD/Units (2018-2023)
  • Figure 13. Global Biosimilars Treatment share by Players 2023 (%)
  • Figure 14. Global Biosimilars Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Biosimilars Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 21. Celltrion Healthcare (South Korea) Revenue, Net Income and Gross profit
  • Figure 22. Celltrion Healthcare (South Korea) Revenue: by Geography 2023
  • Figure 23. Mylan NV (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mylan NV (United States) Revenue: by Geography 2023
  • Figure 25. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. Samsung Bioepis Co. Ltd (South Korea) Revenue, Net Income and Gross profit
  • Figure 28. Samsung Bioepis Co. Ltd (South Korea) Revenue: by Geography 2023
  • Figure 29. Stada Arzneimittel AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Stada Arzneimittel AG (Germany) Revenue: by Geography 2023
  • Figure 31. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2023
  • Figure 33. Intas Pharmaceuticals Ltd (India) Revenue, Net Income and Gross profit
  • Figure 34. Intas Pharmaceuticals Ltd (India) Revenue: by Geography 2023
  • Figure 35. Global Biosimilars Treatment: by Type USD Million (2025-2030)
  • Figure 36. Global Biosimilars Treatment: by Application USD Million (2025-2030)
  • Figure 37. Global Biosimilars Treatment: by Manufacturing USD Million (2025-2030)
  • Figure 38. South America Biosimilars Treatment Share (%), by Country
  • Figure 39. Asia Pacific Biosimilars Treatment Share (%), by Country
  • Figure 40. Europe Biosimilars Treatment Share (%), by Country
  • Figure 41. MEA Biosimilars Treatment Share (%), by Country
  • Figure 42. North America Biosimilars Treatment Share (%), by Country
  • Figure 43. Global Biosimilars Treatment: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Eli Lilly and Company (United States)
  • Celltrion Healthcare (South Korea)
  • Mylan NV (United States)
  • Novartis AG (Switzerland)
  • Samsung Bioepis Co. Ltd (South Korea)
  • Stada Arzneimittel AG (Germany)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Intas Pharmaceuticals Ltd (India)
Additional players considered in the study are as follows:
LG Life Sciences (South Korea) , Biocon (India) , Dr. Reddy’s Laboratories (India)
Select User Access Type

Key Highlights of Report


Mar 2024 210 Pages 81 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Biosimilars Treatment Market Quantitative research analysis
Global Biosimilars Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), Eli Lilly and Company (United States), Celltrion Healthcare (South Korea), Mylan NV (United States), Novartis AG (Switzerland), Samsung Bioepis Co. Ltd (South Korea), Stada Arzneimittel AG (Germany), Teva Pharmaceutical Industries Ltd (Israel) and Intas Pharmaceuticals Ltd (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Collaboration and Tie Up Of Leading Players " is seen as one of major influencing trends for Biosimilars Treatment Market during projected period 2023-2030.
The Biosimilars Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Biosimilars Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Medicated Health Product Comprehensive Study by Type (Herbal Supplements, Hand Sanitizers, Body Powders, Pain Reliefs, Oral Health Products, Antiperspirant, Deodorant, Others), Sales Channel (Online,...
$ 3450
Hemoglobin A1c Monitoring Comprehensive Study by Type (Ion-exchange, High-performance liquid chromatography (HPLC), Immunoassay, Boronate affinity chromatography, Direct enzymatic assay), Application...
$ 3450
Healthcare Provider Population Health Management Platforms Comprehensive Study by End Users (Healthcare Providers, Healthcare Payers, Other), Organization Size (Small and Medium Size Organization, La...
$ 3650
Bed Monitoring System & Baby Monitoring System Comprehensive Study by Type (Baby, Bed), Application (Home Care, Nursing Home & Assisted Living Facilities), End-User (Homecare, Hospitals, Nursing Home...
$ 3800
Cosmetic Procedures Comprehensive Study by Type (Surgical Procedures {Breast Augmentation, Liposuction, Nose Reshaping, Eyelid Surgery, Tummy Tuck, and Facelift}, Non-Surgical Procedures), Applicatio...
$ 3800
Tokenized Securities Comprehensive Study by Type (Equity Token, Debt Token, Real Asset Tokens, Other), Application (STO, ICO) Players and Region - Global Market Outlook to 2027
$ 3500